ID: ALA2179434

Max Phase: Preclinical

Molecular Formula: C43H83N15O8

Molecular Weight: 938.23

Molecule Type: Protein

Associated Items:

Representations

Canonical SMILES:  CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)C

Standard InChI:  InChI=1S/C43H83N15O8/c1-23(2)20-31(52-27(9)59)38(63)56-33(22-25(5)6)40(65)57-32(21-24(3)4)39(64)54-30(16-13-19-51-43(48)49)37(62)58-34(26(7)8)41(66)55-29(14-10-11-17-44)36(61)53-28(35(45)60)15-12-18-50-42(46)47/h23-26,28-34H,10-22,44H2,1-9H3,(H2,45,60)(H,52,59)(H,53,61)(H,54,64)(H,55,66)(H,56,63)(H,57,65)(H,58,62)(H4,46,47,50)(H4,48,49,51)/t28-,29-,30-,31-,32-,33-,34-/m0/s1

Standard InChI Key:  NTGLPRTZQVMCKO-NXBWRCJVSA-N

Associated Targets(Human)

Furin 909 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Subtilisin/kexin type 6 163 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: ProteinTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 938.23Molecular Weight (Monoisotopic): 937.6549AlogP: -1.66#Rotatable Bonds: 33
Polar Surface Area: 396.61Molecular Species: BASEHBA: 11HBD: 15
#RO5 Violations: 3HBA (Lipinski): 23HBD (Lipinski): 19#RO5 Violations (Lipinski): 3
CX Acidic pKa: 11.74CX Basic pKa: 11.63CX LogP: -2.67CX LogD: -9.52
Aromatic Rings: 0Heavy Atoms: 66QED Weighted: 0.02Np Likeness Score: 0.13

References

1. Levesque C, Fugère M, Kwiatkowska A, Couture F, Desjardins R, Routhier S, Moussette P, Prahl A, Lammek B, Appel JR, Houghten RA, D'Anjou F, Dory YL, Neugebauer W, Day R..  (2012)  The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells.,  55  (23): [PMID:23126600] [10.1021/jm3011178]

Source